DataSheet_1_Distinct Immune Response at 1 Year Post-COVID-19 According to Disease Severity.pdf (1.07 MB)

DataSheet_1_Distinct Immune Response at 1 Year Post-COVID-19 According to Disease Severity.pdf

Download (1.07 MB)
posted on 2022-05-23, 08:00 authored by Chang Kyung Kang, Minji Kim, Jisu Hong, Gwanghun Kim, Soojin Lee, Euijin Chang, Pyoeng Gyun Choe, Nam Joong Kim, Ik Soo Kim, Jun-Young Seo, Daesub Song, Dong-Sup Lee, Hyun Mu Shin, Yong-Woo Kim, Chang-Han Lee, Wan Beom Park, Hang-Rae Kim, Myoung-don Oh

Despite the fact of ongoing worldwide vaccination programs for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), understanding longevity, breadth, and type of immune response to coronavirus disease-19 (COVID-19) is still important to optimize the vaccination strategy and estimate the risk of reinfection. Therefore, we performed thorough immunological assessments 1 year post-COVID-19 with different severity.


We analyzed peripheral blood mononuclear cells and plasma samples at 1 year post-COVID-19 in patients who experienced asymptomatic, mild, and severe illness to assess titers of various isotypes of antibodies (Abs) against SARS-CoV-2 antigens, phagocytic capability, and memory B- and T-cell responses.


A total of 24 patients (7, 9, and 8 asymptomatic, mild, and severe patients, respectively) and eight healthy volunteers were included in this study. We firstly showed that disease severity is correlated with parameters of immune responses at 1 year post-COVID-19 that play an important role in protecting against reinfection with SARS-CoV-2, namely, the phagocytic capacity of Abs and memory B-cell responses.


Various immune responses at 1 year post-COVID-19, particularly the phagocytic capacity and memory B-cell responses, were dependent on the severity of the prior COVID-19. Our data could provide a clue for a tailored vaccination strategy after natural infection according to the severity of COVID-19.